The business strategies of companies involved in chiral drug development were cast into doubt in October after Eli Lilly (Indianapolis, IL) decided not to pursue the development of R-fluoxetine ...

Students should be able to represent and classify stereoisomeric relationships and evaluate the implications of synthesizing small molecules for use as chiral drugs. Students should be able to ...

Developing racemic (mixed-enantiomer) drugs is on the way out, industry analysts say, because pharmaceutical companies must evaluate the individual enantiomers and the combination. "Nearly every ...